NKMAX, 'Complete Tumor Remission in Terminal Cancer Patients Draws Attention'... SuperNK Efficacy and Safety Confirmed

[Asia Economy Reporter Hyungsoo Park] NKMax's U.S. subsidiary, NKGen Biotech, announced on the 20th that it will present the results of a total of 8 patients with advanced sarcoma at the European Society for Medical Oncology (ESMO), one of the world's top three oncology conferences.

The 8 patients are receiving treatment with SuperNK (SNK01) under compassionate use approval from the U.S. Food and Drug Administration (FDA), separate from clinical trials.

Previously, NKMax disclosed that among the compassionate use approved patients, complete remission (CR) where tumors disappeared and partial remission (PR) where tumor size was reduced were observed in 2 patients.

The patient confirmed with complete remission was a stage 5 connective tissue-type undifferentiated pleomorphic sarcoma patient with tumors spread throughout the lungs, abdomen, and pelvis. After 28 months of combined treatment with SNK01 and Keytruda (Pembrolizumab), the cancer completely disappeared. The stage 5 osteosarcoma patient confirmed with partial remission also had cancer metastasized throughout the lungs, abdomen, pelvis, and liver, but after a total of 11 administrations of SNK01 and Keytruda, tumor size decreased by 75% in the liver and 55% in other areas.

All these patients had PD-L1 expression rates that were negative or below 10%, showing no response to existing immune checkpoint inhibitors and chemotherapy, which confirmed the efficacy of SNK01. Additionally, the company stated that no side effects caused by SNK01 were observed even after repeated administrations in both patients, securing safety as well.

NKMax plans to disclose data on the remaining 6 patients, including these patients, at ESMO held in France this September.

An NKMax official said, "The results of complete and partial remission in treating malignant sarcoma patients prove the efficacy and safety of SNK01," adding, "Outstanding effects of SNK01 are expected in the remaining 6 compassionate use approved patients, and detailed data will be disclosed at the conference."

This content was produced with the assistance of AI translation services.